John Carbona

John Carbona is the former CEO of AveXis, a biotech startup that developed Zolgensma, the groundbreaking gene therapy for spinal muscular atrophy (SMA). His leadership and management played a critical role in transitioning the therapy from research to commercialization, significantly impacting drug pricing discussions.